Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma | NEJM – nejm.org

by

  1. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma | NEJM nejm.org
  2. Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down FiercePharma
  3. CAR-T cancer therapy reduces risk of multiple myeloma relapse STAT
  4. CAR-T Makes Its Case for Earlier Use in Multiple Myeloma Medpage Today
  5. Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study Yahoo Finance
  6. View Full Coverage on Google News

Read original article here

Leave a Comment